. Author manuscript; available in PMC: 2013 Sep 27.

Published in final edited form as: Clin Pharmacol Ther. 2012 Jun 27;92(2):235–242. doi: 10.1038/clpt.2012.66

Table 3.

Number of preventable adverse events for the VUMC sample with an effective preemptive genotyping and mitigation strategy program.

Medication	Adverse Event	Gene	Ancestry	Risk Strata (G=0, G=1, G=2)	Risk stratum prevalence [pr(G=0), pr(G=1), pr(G=2)]	N_med	Overall Event Probability^*	NP_med,g,1 (number of events prevented)
Medication	Adverse Event	Gene	Ancestry	Risk Strata (G=0, G=1, G=2)	Risk stratum prevalence [pr(G=0), pr(G=1), pr(G=2)]	N_med	Overall Event Probability^*	G=1	G=2	Total (G=1+G=2)
Abacavir (29)	Reaction within first 6 weeks of treatment	HLA-B*5701 allele	All	(Absent, Present,--)	[0.944, 0.056, --]	87	--	3 (3, 3)	--	3 (3, 3)
Azathioprine (30)	Myelosuppression (leukopenia) after at least 3 months	TPMT activity	All	(CA, 1 VA,--)	[0.898, 0.102, --]	878	0.098	17 (13, 21)	--	17 (13, 21)
Clopidogrel (31)	Myocardial infarction, death, or stroke	CYP2C192 or 3 or 4 or 5	All	(CA, 1 VA, 2 VA)	[0.715, 0.263, 0.022]	6361	0.089	71 (13, 131)	8 (3, 16)	79 (23, 139)
Simvastatin (11)	Myopathy during follow-up (average of 6 years)	SLCO1B1 rs4149056	All	(TT, CT, CC)	[0.7225, 0.255, 0.0225]	17631	0.003	14 (4, 25)	5 (1, 14)	19 (8, 30)
Tamoxifen (10)	Breast cancer recurrence at 9 years of follow-up	CYP2D6 (IM or PM)	EA	(EM, IM, PM)	[0.62, 0.33, 0.05]	540	0.186	11 (1, 22)	4 (0, 9)	15 (4, 26)
Warfarin (32)	All bleeding events	carrier of CYP2C9*2	EA	(CA, ≥1 VA, --)	[0.729, 0.271, --]	6651	0.13	172 (34, 316)	--	172 (34, 316)
Warfarin (32)	All bleeding events	carrier of CYP2C9*3	EA	(CA, ≥1 VA, --)	[0.851, 0.149, --]	6651	0.13	93 (8, 193)	--	93 (8, 193)

Total										398 (225, 583)

$CA = common$ allele; $VA = variant$ allele; $EM = extensive$ metabolizer; $IM = intermediate$ metabolizer; $PM = poor$ metabolizer.

N_med represents the number of individuals exposed to the medication within five years of the medical home date.

Assumed probability of the adverse event across all individuals receiving the medication. This value was not required for NP_med,g,1 calculations when examining abacavir because event rates reported(26) within genetic risk strata were used directly. We refer readers to the appendix for a sensitivity analysis that examines the number of preventable adverse events for varying assumed adverse event rates.